drugset / Trial / NCT01854710

ADASUVE 2-dose Thorough QT/QTc Study

NCT01854710

Phase 4 Completed 60 enrolled Alexza Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindOther

Summary

Assess the potential effects on the QT interval of 2 consecutive doses of ADASUVE administered 2 hours apart, in relation to placebo and an active control in healthy volunteers.

Timeline

Start
2013-05
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject loxapine Small molecule 10 mg Inhaled

Indications

No indication recorded.